Fundraising Fox
🦊/Companies
Sign in

Casma Therapeutics

Boston, US · 7 known investors

Find your way into Casma Therapeutics

25 people in our graph share verified history with the Casma Therapeutics team — schools, employers, funds. One of them is your warm intro.

Luke Evninunlockedknows James Hurley · together at University of California, San Francisco (overlapped)
×3knows the team · via University of California, San Francisco
×2knows the team · via Casma Therapeutics
×6knows the team · via National Institutes of Health (NIH): Intramural Research Program (IRP)

Casma is a biotech company developing technology that uses the autophagy pathway to degrade disease targets for therapeutic applications. The company combines molecular biology expertise with a proprietary discovery platform to identify and eliminate disease-causing cellular elements.

BiotechDeep TechHealthtech

Founders & leadership

ABAndrea Ballabio
Andrea BallabioFounder
BLBeth Levine
Beth LevineFounder
HV
Herbert VirginFounder
JHJames Hurley
James HurleyinFounderJames Hurley is founder of Casma Therapeutics, a biotech company developing autophagy-based therapeutics to degrade disease targets. His research background encompasses membrane biology, with particular focus on mechanisms relevant to neurodegeneration and viral infection.

Investors · 7

Astellas Venture Management LLC✓ verifiedSouth San Francisco · $200K – $5M
Third Rock Ventures✓ verifiedBoston · $100K – $5M
Eisai Innovation, Inc.San Francisco
Ono Venture Investment, Inc.South San Francisco
The Column GroupreportedSan Francisco · $30M

Also in the syndicate · 2

Eventide Asset ManagementSchroder Adveq

Funding

SEC filings, press & company announcements

$50M disclosed across 1 of 2 rounds · 2020–2022

Source: company announcements and press reports — follow each round's link for the claim.

Founder mafia

2 people who came through Casma Therapeutics went on to found or lead other companies.

Tim FunnellFounding team: Corporate DevelopmentFounded Ascend Advanced TherapiesNagesh MahanthappaIndependent DirectorFounded Scholar Rock

In the news

Casma Therapeutics Receives MJFF Support to Advance Research on TRPML1 in Parkinson’s Disease - Casma Therapeuticscasmatx.com · Mar 2026Exclusive: After cutting most staff, Casma eyes path to clinic with its first autophagy-boosting drugendpoints.news · Jun 2025Casma Therapeutics Raises $46.0 M in Series C Fundingbusinesswire.com · Nov 2022Casma Therapeutics Raises $50 Million to Advance New Therapies for Rare Diseases - Global Genesglobalgenes.org · Sep 2020Casma Therapeutics Raises $50M in Series B Financing - FinSMEsfinsmes.com · Sep 2020

Frequently asked questions

What does Casma Therapeutics do?
Casma is a biotech company developing technology that uses the autophagy pathway to degrade disease targets for therapeutic applications. The company combines molecular biology expertise with a proprietary discovery platform to identify and eliminate disease-causing cellular elements.
Who founded Casma Therapeutics?
Casma Therapeutics was founded by Andrea Ballabio, Beth Levine, Herbert Virgin, James Hurley.
Who are Casma Therapeutics's investors?
Casma Therapeutics's investors include Astellas Venture Management LLC, Third Rock Ventures, Eisai Innovation, Inc., Ono Venture Investment, Inc., The Column Group.
How much funding has Casma Therapeutics raised?
Casma Therapeutics has disclosed $50M raised across 1 of its 2 known rounds.
Where is Casma Therapeutics headquartered?
Casma Therapeutics is headquartered in Boston, US.